Efficacy of verapamil inhalation in treatment of COPD

Evaluation of nebulised verapamil in improving respiratory symptoms and indexes in chronic obstructive pulmonary disease: a randomized and double blind study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170210032478N2

Enrollment

Registered

2018-10-17

Start date

2018-07-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease. Diseases of the respiratory system

Interventions

Intervention 1: Intervention group: inhaled verapamil. Intervention 2: Control group: placebo via normal saline nebolizer.

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: All admitted COPD patients GOLD stage : 1-4

Exclusion criteria

Exclusion criteria: Pregnancy Sever hepatic dysfunction Hypotension Arrhythmia Cardiac output less than 40% Verapamil hypersensitivity Co- administration of beta adrenergic Bradicardia Other respiratory diseases along with COPD Sever renal dysfunction

Design outcomes

Primary

Measure	Time frame
O2 saturation. Timepoint: Baseline resentment before study and 20 min after administration. Method of measurement: puls oxymetery.;Borg scale. Timepoint: Baseline resentment before study and 20 min after administration. Method of measurement: questionare.	—

Secondary

Measure	Time frame
FEV1. Timepoint: Baseline and 20 min after intervention. Method of measurement: Lung Function Test.;FVC. Timepoint: Baseline and 20 min after intervention. Method of measurement: Lung Function Test.;TLC. Timepoint: Baseline and 20 min after intervention. Method of measurement: body box pletismograghy.;Airway Resistant. Timepoint: Baseline and 20 min after imtervention. Method of measurement: Body box pletismography.	—

Measure

Time frame

FEV1. Timepoint: Baseline and 20 min after intervention. Method of measurement: Lung Function Test.;FVC. Timepoint: Baseline and 20 min after intervention. Method of measurement: Lung Function Test.;TLC. Timepoint: Baseline and 20 min after intervention. Method of measurement: body box pletismograghy.;Airway Resistant. Timepoint: Baseline and 20 min after imtervention. Method of measurement: Body box pletismography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRama Bozorgmehr

Tehran University of Medical Sciences

r_bozorgmehr@tums.ac.ir+98 21 6119 0111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026